

February 01, 2023

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Reg.: Board Meeting on February 14, 2023 for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2022

Dear Sir.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that:

- (i) a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, February 14, 2023 at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2022;
- (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company; and
- (iii) with reference to our earlier announcement dated December 29, 2022 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16, 2023 and the same will re-open from February 17, 2023.

This is for your kind information and record please.

Thanking you, Sincerely yours,

For Panacea Biotec Ltd.

Group CFO and Head Legal

& Company Secretary

B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070